Skip to main content
Erschienen in: Der Hautarzt 11/2016

28.09.2016 | Plattenepithelkarzinom der Haut | Leitthema

Kutanes Plattenepithelkarzinom

verfasst von: PD Dr. med. U. Leiter, R. Gutzmer, M. Alter, C. Ulrich, A. S. Lonsdorf, M. M. Sachse, U. Hillen

Erschienen in: Die Dermatologie | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Plattenepithelkarzinom (PEK) der Haut ist eine der häufigsten Krebsarten der kaukasischen Population und hat einen Anteil von 20 % aller malignen Hauttumoren. Die Diagnose basiert auf der klinischen Untersuchung. Eine Exzision und histologische Sicherung sind bei allen klinisch verdächtigen Läsionen erforderlich, um eine prognostische Einschätzung und korrekte Behandlung zu ermöglichen. Die Therapie der ersten Wahl ist die vollständige Exzision mit histologischer Schnittrandkontrolle. Eine Sentinellymphknotenbiopsie (SLNB) kann bei PEK >6 mm Tumordicke angewandt werden, derzeit liegt aber noch keine klare Evidenz bezüglich der prognostischen und therapeutischen Aussagekraft vor. Die Radiatio kann eine Alternative zur Chirurgie bei inoperablen PEKs darstellen oder adjuvant bei hohem Rezidivrisiko erwogen werden. Im fernmetastasierten Stadium können verschiedene Chemotherapeutika, EGFR („epidermal growth factor receptor“)-Inhibitoren oder Immun-Checkpoint-Blocker eingesetzt werden. Da die Evidenz hier jedoch gering ist, sollte eine medikamentöse Therapie vorzugsweise in klinischen Studien erfolgen. Die Nachsorge sollte risikoadaptiert stattfinden und schließt primär eine dermatologische Kontrolle – bei Hochrisikopatienten ergänzt um Ultraschalluntersuchungen – ein.
Literatur
1.
Zurück zum Zitat Alter M, Satzger I, Schrem H, Kaltenborn A, Kapp A, Gutzmer R (2014) Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J Dtsch Dermatol Ges 12:480–488PubMed Alter M, Satzger I, Schrem H, Kaltenborn A, Kapp A, Gutzmer R (2014) Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J Dtsch Dermatol Ges 12:480–488PubMed
2.
Zurück zum Zitat Association of Population-based Cancer Registries in Germany (2011) Incidence and mortality of cancer in the German federal states. In: GEKID-Atlas. GEKID, Saarbücken Association of Population-based Cancer Registries in Germany (2011) Incidence and mortality of cancer in the German federal states. In: GEKID-Atlas. GEKID, Saarbücken
3.
Zurück zum Zitat Berg D, Otley CC (2002) Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 47:1–17 (quiz 18–20)CrossRefPubMed Berg D, Otley CC (2002) Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 47:1–17 (quiz 18–20)CrossRefPubMed
4.
Zurück zum Zitat Borradori L, Sutton B, Shayesteh P, Daniels GA (2016) Rescue therapy with anti-programmed cell death protein 1 inhibitors (PD-1) of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in 5 cases. Br J Dermatol. doi:10.1111/bjd.14642 Borradori L, Sutton B, Shayesteh P, Daniels GA (2016) Rescue therapy with anti-programmed cell death protein 1 inhibitors (PD-1) of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in 5 cases. Br J Dermatol. doi:10.​1111/​bjd.​14642
5.
Zurück zum Zitat Brantsch KD, Meisner C, Schönfisch B, Trilling B, Wehner-Caroli J, Röcken M, Breuninger H (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9:713–720CrossRefPubMed Brantsch KD, Meisner C, Schönfisch B, Trilling B, Wehner-Caroli J, Röcken M, Breuninger H (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9:713–720CrossRefPubMed
6.
Zurück zum Zitat Brem R, Li F, Montaner B, Reelfs O, Karran P (2010) DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation. Oncogene 29:3953–3963CrossRefPubMedPubMedCentral Brem R, Li F, Montaner B, Reelfs O, Karran P (2010) DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation. Oncogene 29:3953–3963CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Breuninger H, Brantsch K, Eigentler T, Hafner HM (2012) Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges 10:579–586PubMed Breuninger H, Brantsch K, Eigentler T, Hafner HM (2012) Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges 10:579–586PubMed
8.
Zurück zum Zitat Breuninger H, Eigentler T, Bootz F, Hauschild A, Kortmann RD, Wolff K, Stockfleth E, Szeimies RM, Rompel R, Garbe C, Grabbe S (2013) Brief S2k guidelines – cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 11(Suppl 3):37–47CrossRefPubMed Breuninger H, Eigentler T, Bootz F, Hauschild A, Kortmann RD, Wolff K, Stockfleth E, Szeimies RM, Rompel R, Garbe C, Grabbe S (2013) Brief S2k guidelines – cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 11(Suppl 3):37–47CrossRefPubMed
9.
Zurück zum Zitat Chang AL, Kim J, Luciano R, Sullivan-Chang L, Colevas AD (2016) A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatol 152:106–108CrossRefPubMed Chang AL, Kim J, Luciano R, Sullivan-Chang L, Colevas AD (2016) A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatol 152:106–108CrossRefPubMed
10.
Zurück zum Zitat Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL (2015) A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 373:1618–1626CrossRefPubMed Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL (2015) A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 373:1618–1626CrossRefPubMed
11.
Zurück zum Zitat Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ (2013) Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 133:1188–1196CrossRefPubMed Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ (2013) Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 133:1188–1196CrossRefPubMed
12.
Zurück zum Zitat DeTemple V, Satzger I, Walter A, Schaper K, Gutzmer R (2016) Effects of mTOR inhibitors on cytokine production and differentiation in keratinocytes. Exp Dermatol. doi:10.1111/exd.13079 PubMed DeTemple V, Satzger I, Walter A, Schaper K, Gutzmer R (2016) Effects of mTOR inhibitors on cytokine production and differentiation in keratinocytes. Exp Dermatol. doi:10.​1111/​exd.​13079 PubMed
13.
14.
Zurück zum Zitat English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL (1998) Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer 76:628–634CrossRefPubMed English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL (1998) Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer 76:628–634CrossRefPubMed
15.
Zurück zum Zitat Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348:1681–1691CrossRefPubMed Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348:1681–1691CrossRefPubMed
16.
Zurück zum Zitat Euvrard S, Kanitakis J, Decullier E, Butnaru AC, Lefrancois N, Boissonnat P, Sebbag L, Garnier JL, Pouteil-Noble C, Cahen R, Morelon E, Touraine JL, Claudy A, Chapuis F (2006) Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 81:1093–1100CrossRefPubMed Euvrard S, Kanitakis J, Decullier E, Butnaru AC, Lefrancois N, Boissonnat P, Sebbag L, Garnier JL, Pouteil-Noble C, Cahen R, Morelon E, Touraine JL, Claudy A, Chapuis F (2006) Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 81:1093–1100CrossRefPubMed
17.
Zurück zum Zitat Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339CrossRefPubMed Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339CrossRefPubMed
18.
Zurück zum Zitat Geissler EK, Schlitt HJ, Thomas G (2008) mTOR, cancer and transplantation. Am J Transplant 8:2212–2218CrossRefPubMed Geissler EK, Schlitt HJ, Thomas G (2008) mTOR, cancer and transplantation. Am J Transplant 8:2212–2218CrossRefPubMed
19.
Zurück zum Zitat Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM (1997) Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 349:398CrossRefPubMed Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM (1997) Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 349:398CrossRefPubMed
20.
Zurück zum Zitat Han W, Ming M, He TC, He YY (2010) Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem 285:11369–11377CrossRefPubMedPubMedCentral Han W, Ming M, He TC, He YY (2010) Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem 285:11369–11377CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Harwood CA, Mesher D, McGregor JM, Mitchell L, Leedham-Green M, Raftery M, Cerio R, Leigh IM, Sasieni P, Proby CM (2013) A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant 13:119–129CrossRefPubMed Harwood CA, Mesher D, McGregor JM, Mitchell L, Leedham-Green M, Raftery M, Cerio R, Leigh IM, Sasieni P, Proby CM (2013) A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant 13:119–129CrossRefPubMed
22.
Zurück zum Zitat Hillen U, Ulrich M, Alter M, Becker JC, Gutzmer R, Leiter U, Lonsdorf A, Messerschmidt A, Ulrich C (2014) Cutaneous squamous cell carcinoma: a review with consideration of special patient groups. Hautarzt 65:590–599CrossRefPubMed Hillen U, Ulrich M, Alter M, Becker JC, Gutzmer R, Leiter U, Lonsdorf A, Messerschmidt A, Ulrich C (2014) Cutaneous squamous cell carcinoma: a review with consideration of special patient groups. Hautarzt 65:590–599CrossRefPubMed
23.
Zurück zum Zitat Hollestein LM, de Vries E, Nijsten T (2012) Trends of cutaneous squamous cell carcinoma in the netherlands: increased incidence rates, but stable relative survival and mortality 1989–2008. Eur J Cancer 48:2046–2053CrossRefPubMed Hollestein LM, de Vries E, Nijsten T (2012) Trends of cutaneous squamous cell carcinoma in the netherlands: increased incidence rates, but stable relative survival and mortality 1989–2008. Eur J Cancer 48:2046–2053CrossRefPubMed
24.
Zurück zum Zitat Karia PS, Han J, Schmults CD (2013) Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 68:957–966CrossRefPubMed Karia PS, Han J, Schmults CD (2013) Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 68:957–966CrossRefPubMed
25.
Zurück zum Zitat Katalinic A, Kunze U, Schafer T (2003) Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 149:1200–1206CrossRefPubMed Katalinic A, Kunze U, Schafer T (2003) Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 149:1200–1206CrossRefPubMed
26.
Zurück zum Zitat Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK (2004) Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77:1319–1326CrossRefPubMed Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK (2004) Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77:1319–1326CrossRefPubMed
27.
Zurück zum Zitat Leiter U, Eigentler T, Garbe C (2014) Epidemiology of skin cancer. Adv Exp Med Biol 810:120–140PubMed Leiter U, Eigentler T, Garbe C (2014) Epidemiology of skin cancer. Adv Exp Med Biol 810:120–140PubMed
28.
Zurück zum Zitat Levine DE, Karia PS, Schmults CD (2015) Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study. JAMA Dermatol 151:1220–1225CrossRefPubMed Levine DE, Karia PS, Schmults CD (2015) Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study. JAMA Dermatol 151:1220–1225CrossRefPubMed
29.
Zurück zum Zitat Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS (2012) A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 18:1435–1446CrossRefPubMed Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS (2012) A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 18:1435–1446CrossRefPubMed
30.
Zurück zum Zitat Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143:390–399.e1CrossRefPubMedPubMedCentral Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143:390–399.e1CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Lott DG, Manz R, Koch C, Lorenz RR (2010) Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 90:683–687CrossRefPubMed Lott DG, Manz R, Koch C, Lorenz RR (2010) Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 90:683–687CrossRefPubMed
32.
Zurück zum Zitat Marcil I, Stern RS (2000) Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 136:1524–1530CrossRefPubMed Marcil I, Stern RS (2000) Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 136:1524–1530CrossRefPubMed
33.
Zurück zum Zitat Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, Wedge DC, Fullam A, Alexandrov LB, Tubio JM, Stebbings L, Menzies A, Widaa S, Stratton MR, Jones PH, Campbell PJ (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348(6237):880–886. doi:10.1126/science.aaa6806 CrossRefPubMedPubMedCentral Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, Wedge DC, Fullam A, Alexandrov LB, Tubio JM, Stebbings L, Menzies A, Widaa S, Stratton MR, Jones PH, Campbell PJ (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348(6237):880–886. doi:10.​1126/​science.​aaa6806 CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentre F, Avril MF (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29:3419–3426CrossRefPubMed Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentre F, Avril MF (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29:3419–3426CrossRefPubMed
35.
Zurück zum Zitat Mecca C, Ponzetti A, Caliendo V, Ciuffreda L, Lista P (2012) Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol 22:758–761PubMed Mecca C, Ponzetti A, Caliendo V, Ciuffreda L, Lista P (2012) Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol 22:758–761PubMed
36.
Zurück zum Zitat Mehrany K, Weenig RH, Lee KK, Pittelkow MR, Otley CC (2005) Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol 53:1067–1071CrossRefPubMed Mehrany K, Weenig RH, Lee KK, Pittelkow MR, Otley CC (2005) Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol 53:1067–1071CrossRefPubMed
37.
Zurück zum Zitat Mehrany K, Weenig RH, Pittelkow MR, Roenigk RK, Otley CC (2005) High recurrence rates of squamous cell carcinoma after Mohs’surgery in patients with chronic lymphocytic leukemia. Dermatol Surg 31:38–42 (discussion 42)CrossRefPubMed Mehrany K, Weenig RH, Pittelkow MR, Roenigk RK, Otley CC (2005) High recurrence rates of squamous cell carcinoma after Mohs’surgery in patients with chronic lymphocytic leukemia. Dermatol Surg 31:38–42 (discussion 42)CrossRefPubMed
38.
Zurück zum Zitat Nappi O, Wick MR, Pettinato G, Ghiselli RW, Swanson PE (1992) Pseudovascular adenoid squamous cell carcinoma of the skin. A neoplasm that may be mistaken for angiosarcoma. Am J Surg Pathol 16:429–438CrossRefPubMed Nappi O, Wick MR, Pettinato G, Ghiselli RW, Swanson PE (1992) Pseudovascular adenoid squamous cell carcinoma of the skin. A neoplasm that may be mistaken for angiosarcoma. Am J Surg Pathol 16:429–438CrossRefPubMed
39.
Zurück zum Zitat O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874CrossRefPubMedPubMedCentral O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T (2010) Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 105:1480–1487CrossRefPubMed Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T (2010) Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 105:1480–1487CrossRefPubMed
41.
Zurück zum Zitat Renzi C, Caggiati A, Mannooranparampil TJ, Passarelli F, Tartaglione G, Pennasilico GM, Cecconi S, Potenza C, Pasquini P (2007) Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol 33:364–369CrossRefPubMed Renzi C, Caggiati A, Mannooranparampil TJ, Passarelli F, Tartaglione G, Pennasilico GM, Cecconi S, Potenza C, Pasquini P (2007) Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol 33:364–369CrossRefPubMed
42.
Zurück zum Zitat Rettberg P, Horneck G (1999) Intrinsic and extrinsic biomarkers for the assessment of risks from environmental UV radiation. J Epidemiol 9(6 Suppl):78–83CrossRef Rettberg P, Horneck G (1999) Intrinsic and extrinsic biomarkers for the assessment of risks from environmental UV radiation. J Epidemiol 9(6 Suppl):78–83CrossRef
43.
Zurück zum Zitat Ross AS, Schmults CD (2006) Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg 32:1309–1321PubMed Ross AS, Schmults CD (2006) Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg 32:1309–1321PubMed
44.
Zurück zum Zitat Royle JA, Baade PD, Joske D, Girschik J, Fritschi L (2011) Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 105:1076–1081CrossRefPubMedPubMedCentral Royle JA, Baade PD, Joske D, Girschik J, Fritschi L (2011) Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 105:1076–1081CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Schmitt AR, Brewer JD, Bordeaux JS, Baum CL (2014) Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 150:19–24CrossRefPubMed Schmitt AR, Brewer JD, Bordeaux JS, Baum CL (2014) Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 150:19–24CrossRefPubMed
46.
Zurück zum Zitat Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA (2013) Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 149:541–547CrossRefPubMed Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA (2013) Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 149:541–547CrossRefPubMed
47.
Zurück zum Zitat Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R (2012) Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 27:385–389CrossRefPubMed Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R (2012) Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 27:385–389CrossRefPubMed
48.
Zurück zum Zitat Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag P, Middleton MR, Bastholt L, Testori A, Grob JJ, on behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), the European Organization for Research and Treatment of Cancer (EORTC) (2015) Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 51:1989–2007CrossRefPubMed Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag P, Middleton MR, Bastholt L, Testori A, Grob JJ, on behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), the European Organization for Research and Treatment of Cancer (EORTC) (2015) Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 51:1989–2007CrossRefPubMed
49.
Zurück zum Zitat Surjana D, Halliday GM, Martin AJ, Moloney FJ, Damian DL (2012) Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 132:1497–1500CrossRefPubMed Surjana D, Halliday GM, Martin AJ, Moloney FJ, Damian DL (2012) Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 132:1497–1500CrossRefPubMed
50.
Zurück zum Zitat Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL (2016) Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol 152:419–428CrossRefPubMed Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL (2016) Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol 152:419–428CrossRefPubMed
51.
Zurück zum Zitat Weedon DMR, Kao GF, Harwood CA (2006) Keratinocytic tumors. IARC Press, Lyon Weedon DMR, Kao GF, Harwood CA (2006) Keratinocytic tumors. IARC Press, Lyon
52.
Zurück zum Zitat Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Frohling S, Penzel R, Enk A, Hassel JC (2016) Anti-PD-1 therapy in nonmelanoma skin cancer. Br J Dermatol. doi:10.1111/bjd.14664 Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Frohling S, Penzel R, Enk A, Hassel JC (2016) Anti-PD-1 therapy in nonmelanoma skin cancer. Br J Dermatol. doi:10.​1111/​bjd.​14664
53.
Zurück zum Zitat Xiang F, Lucas R, Hales S, Neale R (2014) Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978–2012: empirical relationships. JAMA Dermatol 150:1063–1071CrossRefPubMed Xiang F, Lucas R, Hales S, Neale R (2014) Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978–2012: empirical relationships. JAMA Dermatol 150:1063–1071CrossRefPubMed
54.
Zurück zum Zitat Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65:253–261 (quiz 262)CrossRefPubMed Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65:253–261 (quiz 262)CrossRefPubMed
Metadaten
Titel
Kutanes Plattenepithelkarzinom
verfasst von
PD Dr. med. U. Leiter
R. Gutzmer
M. Alter
C. Ulrich
A. S. Lonsdorf
M. M. Sachse
U. Hillen
Publikationsdatum
28.09.2016
Verlag
Springer Medizin
Erschienen in
Die Dermatologie / Ausgabe 11/2016
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-016-3875-2

Weitere Artikel der Ausgabe 11/2016

Der Hautarzt 11/2016 Zur Ausgabe

Einführung zum Thema

Epitheliale Hauttumoren

Passend zum Thema

ANZEIGE

Umfrage: Topika mit Dexpanthenol bei Radiodermatitis empfohlen

In der topischen Prävention der akuten Radiodermatitis werden Zubereitungen mit Dexpanthenol oder Harnstoff von deutschsprachigen Fachkreisen in der Radioonkologie am häufigsten empfohlen und als am wirksamsten bewertet. Bei der Behandlung der strahlenbedingten Hautschäden liegen Topika mit Dexpanthenol oder Kortikosteroide vorn [1]. 

ANZEIGE

Handekzem: Adhärenz bei topischer Therapie nicht zufriedenstellend

Einer klinischen Studie zufolge wendet nur etwa die Hälfte der Ekzem-Patient:innen ihre topische Therapie mit Kortikosteroiden wie verordnet an. Darüber hinaus nahm die Adhärenz im Zeitverlauf weiter ab. Bei einer gleichzeitig applizierten barrierestabilisierenden Basiscreme blieb die Anwendungsfrequenz dagegen über die Zeit stabil [1]. 

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.

Bayer Vital GmbH